Shun Lu

发表

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Jun Ma, Yi-long Wu, Q. Xiu, 2011, The Lancet. Oncology.

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Haidong Wang, Shun Lu, X. Ai, 2014, Amino Acids.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10

Zhen Zhou, Shun Lu, X. Niu, 2017, Molecular medicine reports.

Inhibition of the growth of non-small cell lung cancer by miRNA-1271.

Zhen Zhou, Shun Lu, X. Niu, 2015, American journal of translational research.

Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Sheng He, Mingjiao Sun, L. Xia, 2021, Science China Life Sciences.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.

Shun Lu, Zi-ming Li, S. Lu, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Ying Cheng, M. Satouchi, He-long Zhang, 2022, International Journal of Clinical Oncology.

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

D. Planchard, Shun Lu, X. Ai, 2021, Frontiers in Oncology.

Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.

Yunpeng Liu, Dong Wang, Jie Wang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

[Research status on targeted therapy for squamous cell lung cancer].

Shun Lu, Hong Yuan, S. Lu, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.

Shun Lu, X. Ai, S. Shen, 2015, Biochimie.

FBXL 5-mediated degradation of single-stranded DNA-binding protein hSSB 1 controls DNA damage response

Shun Lu, X. Niu, B. Liu, 2014 .

FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response

Shun Lu, B. Liu, X. Niu, 2014, Nucleic acids research.

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer

Zhen Zhou, Q. Luo, Shun Lu, 2012, Journal of experimental & clinical cancer research : CR.

SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation

Jia Huang, Q. Luo, Shun Lu, 2016, Oncotarget.

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway

W. Xia, Shun Lu, Zi-ming Li, 2016, Oncotarget.

Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Annals of translational medicine.

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

Yangqiu Li, Yingyong Hou, Ying Cheng, 2019, Cancer biology & medicine.

Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis.

Shun Lu, Xiaohua Yang, shunfang yang, 2014, Acta biochimica et biophysica Sinica.

Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer.

Y. Guan, C. Zuo, Jun Zhao, 2008, Molecular medicine reports.

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison

Shun Lu, Yong-feng Yu, F. Zhu, 2022, Journal of clinical medicine.

Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.

Shun Lu, S. Qu, Chenwei Cui, 2022, Future oncology.

The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti‐drug responses in human non‐small cell lung cancer

Shun Lu, X. Niu, Zhiwei Chen, 2014, British journal of pharmacology.

Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism

Jian-min Liu, Shun Lu, Zhu-Gang Wang, 2010, Endocrine.

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Fen Wang, Zhen-ke Wen, Shun Lu, 2021, Annals of translational medicine.

Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma.

Shun Lu, Zhiwei Chen, Yunhua Xu, 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Research progress of positive ALK fusion gene non-small cell lung cancer

Shun Lu, Yong-feng Yu, Ying-lei Liu, 2019 .

Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

Wei Wei, Liu Yang, Shun Lu, 2019, Nature Communications.

A Study of Ethnic Differences in TGF&bgr;1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non–Small-Cell Lung Cancer

Yun Liu, Shun Lu, Daizhan Zhou, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Xue Wu, Y. Shao, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Yi-long Wu, B. Peil, Wei Li, 2018, OncoTargets and therapy.

[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].

Shun Lu, Li Zhang, Yong-feng Yu, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1

Ying Yang, Shun Lu, Zi-ming Li, 2020, Cancer Cell International.

FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.

W. Xia, Min Lu, Shun Lu, 2021, Cellular immunology.

The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

Shun Lu, Yingjia Sun, H. Husain, 2021, Translational lung cancer research.

Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing

Shun Lu, J. Qian, Lan Shen, 2021, International journal of medical sciences.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer

M. Ahn, Yi-long Wu, M. Orlando, 2016, Asia-Pacific journal of clinical oncology.

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

Jin-Ji Yang, K. Lu, Jie Hu, 2019, Cancer biology & therapy.

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yi-long Wu, Q. Xiu, Chengping Hu, 2012 .

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

L. Sequist, Keunchil Park, Yi-long Wu, 2019, Lung cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Ying Cheng, Yi-long Wu, M. Orlando, 2016, Clinical lung cancer.

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Zhen Zhou, Shun Lu, Zhiwei Chen, 2010, Chemotherapy.

Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients

Zhen Zhou, M. Liao, Shun Lu, 2012, Journal of surgical oncology.

Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.

Shun Lu, Zhiwei Chen, Yi-fei Zhang, 2009, Chinese medical journal.

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2020 .

The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Shun Lu, Zong-hai Li, Zhiwei Chen, 2009, Current therapeutic research, clinical and experimental.

Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.

Joe Y. Chang, T. de Baère, S. Senan, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.

Shun Lu, Zi-ming Li, S. Lu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC

G. Zhu, Shun Lu, N. Che, 2021, Cancer medicine.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Keunchil Park, T. Mok, Yi-long Wu, 2018, Lung cancer.

Chinese pediatric and adolescent primary tracheobronchial tumors: a hospital-based study

Shun Lu, Zhiwei Chen, H. Jian, 2011, Pediatric Surgery International.

Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.

Q. Ou, Shun Lu, Hong-gang Ke, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging

Jianping Zhang, Jianping Zhang, Shun Lu, 2019, Oncology reports.

Isolation and characterization of ex vivo expanded mesenchymal stem cells obtained from a surgical patient

Jia Huang, Q. Luo, Q. Tan, 2014, Molecular medicine reports.

Impact of Lymph Node Dissection on Survival and Tumor Recurrence for Patients with Resected cT1-2N0 Small Cell Lung Cancer

Q. Luo, Shun Lu, Yuan Liu, 2022, Annals of Surgical Oncology.

Regulation of SIRT2 levels for human non-small cell lung cancer therapy.

W. Xia, Shun Lu, Q. Xie, 2013, Lung cancer.

Early‐like differentiation status of systemic PD‐1+ CD8 + T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer

Chengping Hu, Jie Zhang, L. Xia, 2022, Clinical & translational immunology.

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

S. Broderick, T. Mitsudomi, Changli Wang, 2021, Clinical Trials.

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

N. Girard, S. Broderick, T. Mitsudomi, 2021 .

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

M. Tsuboi, Jie He, R. Herbst, 2020, The New England journal of medicine.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

S. Ramalingam, M. Saggese, Shun Lu, 2021, Clinical lung cancer.

Long‐term survival in thymic epithelial tumors: A single‐center experience from China

Shun Lu, X. Ai, S. Shen, 2013, Journal of surgical oncology.

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Ping Wang, Ying Cheng, C. Chiu, 2020 .

SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo.

B. Liu, Shun Lu, Yi Zhao, 2015, Cellular signalling.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment

L. Xia, Shun Lu, Yingjia Sun, 2022, Journal of clinical medicine.

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Shun Lu, X. Niu, Yuchen Han, 2022, Frontiers in Immunology.

Immuno-based therapeutic strategies for initial unresectable locally advanced non-small cell lung cancer: a case report

Jia Huang, Q. Luo, Shun Lu, 2020, Translational lung cancer research.

International consensus on severe lung cancer—the first edition

W. Liang, J. Liu, F. Petrella, 2021, Translational lung cancer research.

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.

Yi-long Wu, Jian-hua Chang, Chengping Hu, 2021, Lung cancer.

NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10

Shun Lu, X. Ai, Yingjia Sun, 2015, Oncotarget.

Regulation of β-catenin-mediated esophageal cancer growth and invasion by miR-214.

Shun Lu, Yunhua Xu, S. Lu, 2015, American journal of translational research.

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

J. Yi, Jianxing He, Jinjing Xia, 2022, Cancer medicine.

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.

Ying Cheng, He-long Zhang, N. Yang, 2021, The Lancet. Respiratory medicine.

Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma

W. Xia, L. Xia, Shun Lu, 2021, Translational oncology.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

K. Syrigos, E. Felip, J. Soria, 2015, The Lancet. Oncology.

The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.

W. Xia, Ying Yang, Shun Lu, 2018, Cancer letters.

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

W. Xia, Shun Lu, Jiaxiang Shao, 2017, Journal of experimental & clinical cancer research : CR.

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

X. Chen, Pengxiang Wu, R. Guo, 2023, The Lancet. Respiratory medicine.

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study

L. Xia, Shun Lu, X. Niu, 2022, Journal of clinical medicine.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Haidong Wang, Shun Lu, X. Ai, 2014, Amino Acids.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Ying Cheng, B. Han, Yunpeng Liu, 2012, The Lancet. Oncology.

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

N. Yang, K. Ying, Zhijie Wang, 2020 .

The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2

Shun Lu, X. Niu, Zhiwei Chen, 2014, FEBS letters.

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies

Shun Lu, X. Niu, Zhiwei Chen, 2015, Lung.

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.

Zhen Zhou, Shun Lu, X. Niu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A 3D Ex Vivo Tumor‐Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion

Ying Chen, W. Cui, Zhen Wang, 2023, Advanced biology.

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Ying Cheng, T. Mok, Yi-long Wu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.

Yueping Jin, Huajun Zheng, L. Xia, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Perioperative chemotherapy of stage III N2 non-small cell lung cancer

Shun Lu, Yong-feng Yu, S. Lu, 2009 .

[Perioperative chemotherapy of stage III N2 non-small cell lung cancer.].

Shun Lu, Yong-feng Yu, S. Lu, 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis

Shun Lu, Bin Wu, S. Lu, 2020, Translational lung cancer research.

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

Shun Lu, Lan Gao, L. Luan, 2021, Frontiers in Oncology.

FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer

W. Xia, Shun Lu, X. Niu, 2018, Oncogene.

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort

G. Lippi, M. Mino‐Kenudson, S. Chuai, 2020, Translational lung cancer research.

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients

Shun Lu, Zhiwei Chen, Zheng-bo Song, 2011, Medical oncology.

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

N. Yang, K. Ying, Zhijie Wang, 2021, JAMA oncology.

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Zhen Zhou, G. Jiang, Shun Lu, 2019, Cancer management and research.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Ying Cheng, B. Han, Yunpeng Liu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.

Yang Zhang, Ying Cheng, Yi-long Wu, 2014, Lung cancer.

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

Chengping Hu, Gang Wu, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

A. Marchetti, L. Bubendorf, U. Dafni, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies.

Shun Lu, X. Niu, Zhiwei Chen, 2011, Mutagenesis.

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI

J. Fang, T. Hsia, J. Chen, 2019, Journal of Thoracic Oncology.

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.

D. Ferry, Baolan Li, Shun Lu, 2022, The Lancet. Oncology.

Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial.

C. Chiu, T. Hsia, D. Camidge, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic Alteration During Metastasis of Lung Adenocarcinoma

Jia Huang, Hao Lin, Q. Luo, 2016, Cellular Physiology and Biochemistry.

High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients

J. Heath, Jungwoo Kim, Wei Wei, 2017, Proceedings of the National Academy of Sciences.

EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment

T. Mok, Y. Ichinose, Takao Takahashi, 2016 .

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Zonghai Li, M. Liao, Shun Lu, 2012, Lung cancer.

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.

Bingbing Ni, Jiancheng Yang, L. Xia, 2021, American journal of translational research.

Comprehensive molecular characterizations of stage I–III lung adenocarcinoma with tumor spread through air spaces

Shun Lu, Yuchen Han, R. Zhao, 2023, Frontiers in Genetics.

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Y. Luo, Q. Xiu, Yan Zhang, 2013, Annals of Oncology.

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer

Hongyan Chen, L. Xia, Shun Lu, 2021, Frontiers in Immunology.

Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China

Chunxiao Wu, M. Liao, Shun Lu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer

B. Liu, Shun Lu, Yi Zhao, 2014, Tumor Biology.

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2021 .

PD‐1 blockade augments humoral immunity through ICOS‐mediated CD4+ T cell instruction

P. Ji, Yingying Chen, Yanyun Zhang, 2019, International immunopharmacology.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study

Jian-Ying Zhou, Shun Lu, Jian-ya Zhou, 2021, Translational lung cancer research.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Ying Cheng, Yi-long Wu, Zhi-yong Ma, 2020 .

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Yi-long Wu, Y. Wu, C. Zhou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

M. Liao, X. Hou, Shun Lu, 2010, Lung cancer.

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

Ruilian Xie, Shun Lu, Longqiu Wu, 2021, Annals of translational medicine.

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

N. Reinmuth, Ying Cheng, T. John, 2023, Journal of Clinical Oncology.

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of Clinical Oncology.

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

J. Shih, C. Liam, Shun Lu, 2021, Advances in Therapy.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adverse Effects of Combined Tyrosine Kinase Inhibitors.

Shun Lu, Zi-ming Li, S. Lu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy

P. Ji, L. Xia, Shun Lu, 2021, Cancer science.

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Shun Lu, Jianying Zhou, Chengzhi Zhou, 2023, JCO precision oncology.

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

Ying Cheng, Shun Lu, Jianying Zhou, 2022, Therapeutic advances in medical oncology.

17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway

Q. Luo, Shun Lu, X. Niu, 2015, Journal of cellular and molecular medicine.

Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma

Lei Zhu, Shun Lu, Zhengping Ding, 2016, Cancer medicine.

Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking

T. Mok, Q. Tao, Jia Huang, 2013, OncoTargets and therapy.

FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma

Shun Lu, Zhi Shang, X. Niu, 2019, Journal of Molecular Medicine.

Polymorphisms of microRNA Sequences or Binding Sites and Lung Cancer: A Meta-Analysis and Systematic Review

Shun Lu, X. Niu, Zhiwei Chen, 2013, PloS one.

Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component

Yang Xu, Xue Wu, Y. Shao, 2021, Frontiers in Oncology.

Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8+ T cells with enhanced effector function and anti-tumor response.

Ying Chen, L. Xia, Shun Lu, 2023, Cell reports.

Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Yun Liu, Zhen Zhou, M. Liao, 2017, Clinical Cancer Research.

EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma

Q. Luo, Shun Lu, Hui-quan Gao, 2012, Journal of Cancer Research and Clinical Oncology.

肺鳞癌靶向治疗研究现状

Shun Lu, Hong Yuan, L. Shun, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

C. Dooms, A. Drilon, E. Felip, 2023, Journal of Clinical Oncology.

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Jie Yang, M. Ahn, K. Wilner, 2022, JTO clinical and research reports.

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2022, JTO clinical and research reports.

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

Shun Lu, D. Ding, Yong-feng Yu, 2020, Cancer medicine.

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

T. Yamanaka, M. Ahn, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis

Shun Lu, Yong-feng Yu, Jingqi Zhuang, 2017, Oncotarget.

[Genome wide association study on lung cancer.].

Shun Lu, X. Ai, Xiaomin Niu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1‐Rearranged Non–Small Cell Lung Cancer

Jia Huang, Shun Lu, Jie Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases

Shun Lu, Lei Zhu, Zhengping Ding, 2016, SpringerPlus.

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

Shun Lu, Yong-feng Yu, S. Lu, 2023, Therapeutic advances in medical oncology.

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

Yao Lu, Shun Lu, S. Lu, 2022, Cancers.

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

Shun Lu, Zhuang Yu, Zhehai Wang, 2021 .

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of Thoracic Oncology.

Metformin Inhibits Esophagus Cancer Proliferation through Upregulation of USP7

Shun Lu, Yunhua Xu, S. Lu, 2013, Cellular Physiology and Biochemistry.

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104

W. Xia, Ying Yang, Shun Lu, 2020, Oncogene.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.

N. Yang, Jin-lu Shan, Xiaohua Hu, 2023, Journal of Clinical Oncology.

Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer

Zhen Zhou, M. Liao, Q. Luo, 2013, OncoTargets and therapy.

Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.

Shun Lu, Ziming Li, 2017 .

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting

Jun Zhao, Shun Lu, X. Ai, 2022, Therapeutic advances in medical oncology.

Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification.

Rongrong Chen, Shun Lu, Lei Zhu, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Xiangqian Zheng, Shun Lu, Jianying Zhou, 2023, Therapeutic advances in medical oncology.

Abstract CT031: Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboringMETexon 14 skipping mutations

Z. Xiaodong, Ying Cheng, He-long Zhang, 2019, Clinical Trials.

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Jie Yang, Gregory Riely, F. de Marinis, 2023, Journal of Clinical Oncology.

Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients

Liu Yang, Xiaowei Yan, H. Herschman, 2021, Proceedings of the National Academy of Sciences.

Acetylcholine receptor pathway in lung cancer: New twists to an old story.

Shun Lu, X. Niu, S. Lu, 2014, World journal of clinical oncology.

Angiogenesis in tumorigenesis and the possible rationale for the synergy between angiogenesis inhibitors and CT In 1971

Shun Lu, Shan-Ming Chen, S. Lu, 2015 .

Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.

S. Ou, Shun Lu, X. Ai, 2018, Lung cancer.

Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma

J Zhang, Zhen Zhou, Shun Lu, 2019, Thoracic cancer.

Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.

M. Provencio, J. Spicer, Shun Lu, 2020 .

Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.

Xue Wu, Y. Shao, Q. Ou, 2019, Lung cancer.

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression

Zhen Zhou, M. Liao, Q. Luo, 2017, Oncotarget.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

H. Zhang, Yi-long Wu, B. Han, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

N. Girard, Keunchil Park, L. Paz-Ares, 2020, Frontiers in Oncology.

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer

Zhen Zhou, Q. Luo, Shun Lu, 2012, Journal of experimental & clinical cancer research : CR.

Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma.

Shun Lu, X. Ye, Yong-feng Yu, 2019, Journal of thoracic disease.

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Ying Cheng, T. Mok, Yi-long Wu, 2021, Lung cancer.

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial

T. Mok, J. Yang, S. Morita, 2021, JTO clinical and research reports.

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

Ying Cheng, Shun Lu, Kai Wang, 2022, The oncologist.

Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer

Jianren Gu, B. Shi, Zonghai Li, 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer.

Haiquan Chen, Jing Fang, M. Liao, 2010, Oncology reports.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Jae Cheol Lee, Jih-Hsiang Lee, F. Siddiqui, 2017, Oncotarget.

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Jie Yang, Ying Cheng, T. Hsia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

K. Syrigos, E. Felip, J. Soria, 2018, JAMA oncology.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

C. Chiu, Dong-Wan Kim, G. Chang, 2023, JTO clinical and research reports.

Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).

T. Yamanaka, M. Ahn, Yi-long Wu, 2016 .

Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.

Ying Cheng, He-long Zhang, Cheng Huang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report

Shun Lu, X. Ai, Yingjia Sun, 2021, Translational lung cancer research.

βKlotho is identified as a target for theranostics in non-small cell lung cancer

W. Xia, Shun Lu, W. Ji, 2019, Theranostics.

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing

Shun Lu, W. Ji, Yong-feng Yu, 2021, Annals of translational medicine.

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report

Shun Lu, W. Su, Jing Li, 2019, OncoTargets and therapy.

CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Y. Shu, Y. Wu, N. Yang, 2019, Annals of Oncology.

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Yiping Zhang, S. Cai, C. Xie, 2022, BMC Medicine.

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Shun Lu, Yi Yang, S. Lu, 2019, The oncologist.

Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.

Shun Lu, M. Ye, Jie Zhang, 2016, Pharmacogenomics.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Jie Yang, M. Salto‐Tellez, J. Shih, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer

Yueping Jin, Hao Chen, Jia Huang, 2023, Annals of Surgical Oncology.

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.

Shun Lu, X. Niu, D. Ding, 2014 .

Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2015 .

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling

Shun Lu, Yi Zhao, Yi Yang, 2017, FEBS open bio.

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

Ying Cheng, Yue-Yin Pan, Yong He, 2023, Journal of Cancer Research and Clinical Oncology.

Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Shun Lu, X. Ai, Jie-jun Wang, 2018, BMC Cancer.

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer

Ying Yang, Shun Lu, Tingting Lu, 2020, Cell adhesion & migration.

M. Tsuboi, R. Herbst, Yi-long Wu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.

Shun Lu, Mengxiao Wang, Yong-feng Yu, 2022, Lung cancer.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry

Xiangyun Ye, Jia Wei, Yun-Qin Chen, 2016, Oncotarget.

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Baolan Li, Wei Li, Chengping Hu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and Safety of Anti-Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial.

R. Guo, Shun Lu, Xiangrong Dai, 2023, JTO clinical and research reports.

Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib versus Chemotherapy in East Asian Patients with ALK‐Positive Advanced Non–Small Cell Lung Cancer

T. Mok, Yi-long Wu, K. Wilner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer.

Xiangyun Ye, Ruijun Liu, Shun Lu, 2017, Molecular bioSystems.

PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.

W. Xia, Ying Yang, Shun Lu, 2020, Experimental cell research.

Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway

Lin Xu, Jia Huang, Hao Lin, 2015, International Journal of Clinical Oncology.

Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations.

S. Ou, Shun Lu, Rongrong Chen, 2021, Lung cancer.

Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer

Yingying Chen, L. Xia, Shun Lu, 2021, Frontiers in Molecular Biosciences.

GPC5 rs2352028 Polymorphism and Risk of Lung Cancer in Han Chinese

Yun Liu, Yonglan Zheng, Shun Lu, 2012, Cancer investigation.

Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population

Yun Liu, M. Liao, Shun Lu, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

L. Sequist, K. O'Byrne, T. Mok, 2017, The Patient - Patient-Centered Outcomes Research.

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

Yi-long Wu, Wei Li, Chongrui Xu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Jie Yang, M. Ahn, Dong-Wan Kim, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial.

Ping Wang, Ying Cheng, C. Chiu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

Michael Thomas, E. Felip, S. Shreeve, 2021, Future Oncology.

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.

Shun Lu, Zhiwei Chen, Yong-feng Yu, 2011, Chinese medical journal.

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers

Shun Lu, X. Niu, Zi-ming Li, 2022, Frontiers in Immunology.

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

Baolan Li, Shun Lu, C. Ding, 2023, The Lancet. Respiratory medicine.

Exosomal miR‐499a‐5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma

W. Xia, Shun Lu, W. Ji, 2019, Experimental cell research.

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

Shun Lu, S. Lu, 2019, OncoTargets and therapy.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

K. Syrigos, E. Felip, J. Soria, 2017, Lung cancer.

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

Shun Lu, 2019 .

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

Shun Lu, 2019 .

Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).

Ying Cheng, He-long Zhang, N. Yang, 2020 .

Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer.

M. Liao, Q. Luo, Shun Lu, 2013, Chest.

Shun Lu, X. Niu, D. Ding, 2014, OncoTargets and therapy.

Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer

Jia Huang, Q. Luo, Shun Lu, 2016, Tumor Biology.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer

Christopher I Amos, Murray Favus, Hongwei Wang, 2015, Clinical Cancer Research.

Expert consensus on treatment for stage III non‐small cell lung cancer

W. Liang, Jin-Ji Yang, Long Chen, 2023, Medicine Advances.

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Incidence, time trend, survival, and predictive factors of lung cancer in Shanghai populations].

M. Liao, Shun Lu, Zhiwei Chen, 2007, Zhonghua yi xue za zhi.

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer

Shun Lu, Yi Zhao, Yaxian Yao, 2023, Frontiers in oncology.

Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Danyi Wen, Shun Lu, Jie Zhang, 2018, Cancer communications.

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China

Shun Lu, Yong-feng Yu, H. Ren, 2018, PloS one.

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Shun Lu, M. Ye, F. Tan, 2016, Oncotarget.

Y. Luo, Q. Xiu, Shucai Zhang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance therapy for NSCLC: Consensus and controversy

Shun Lu, Yong-feng Yu, 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Wei Li, C. Bai, Wei Li, 2017, Scientific Reports.

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

T. Mok, Yi-long Wu, K. Wilner, 2016 .

Genomic Alteration During Metastasis of Lung Adenocarcinoma

Jia Huang, Hao Lin, Q. Luo, 2016, Cellular Physiology and Biochemistry.

Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?

Shun Lu, Ziming Li, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes.

Rongrong Chen, Shun Lu, Lei Zhu, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

He-long Zhang, N. Yang, Sanyuan Sun, 2022, JTO clinical and research reports.

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

X. Yi, Xiaohua Hu, Jiexia Zhang, 2020, Clinical Cancer Research.

MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A

Shun Lu, Zhiwei Chen, X. Ye, 2019, International journal of immunopathology and pharmacology.

XBP 1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3 D culture

M. Liao, Shun Lu, Yi Zhao, 2017 .

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

B. Peil, N. Gibson, Wei Li, 2018, OncoTargets and therapy.

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

K. Syrigos, E. Felip, J. Soria, 2017 .

Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists

Shun Lu, W. Ji, Yong-feng Yu, 2021, Annals of translational medicine.

Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report

Shun Lu, Jianying Zhou, Chengzhi Zhou, 2023, Anti-cancer drugs.

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness

Q. Geng, Q. Shen, Yan Li, 2019, EBioMedicine.

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).

Ying Cheng, T. Mok, Yi-long Wu, 2020, Lung cancer.

[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].

Ying Cheng, T. Mok, Yi-long Wu, 2013, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma

Shun Lu, Yuchen Han, H. Jian, 2019, Anti-cancer drugs.

Propensity score matched analysis for the role of surgery in stage Ⅲ small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital.

Shun Lu, Kaixuan Wang, L. Shen, 2021, Lung cancer.

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

B. Peil, N. Gibson, Wei Li, 2018, OncoTargets and Therapy.

Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.

Ying Cheng, Yi-long Wu, B. Han, 2019, Lung cancer.

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Shun Lu, Yan Yu, B. Tang, 2022, Cancer journal.

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

Zhen Zhou, Shun Lu, X. Ai, 2021, BMC Cancer.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients

W. Xia, Q. Luo, Q. Tan, 2016, Oncotarget.

Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).

Geoffrey Liu, J. Yang, S. Popat, 2021, Future oncology.

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer

W. Xia, Ying Yang, Shun Lu, 2019, Oncogenesis.

FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer

W. Xia, Shun Lu, X. Niu, 2018, Oncogene.

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

Akira Inoue, N. Reinmuth, W. Dempke, 2015, Anticancer research.

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models

Shun Lu, Liu Liu, Yuchen Han, 2022, Frontiers in Oncology.

Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.

Qingshan Li, Ying Cheng, R. Guo, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).

Shun Lu, Yuping Sun, Zhuang Yu, 2022, Journal of Clinical Oncology.

Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis

W. Xia, Shun Lu, Jiachen Chen, 2023, Cellular Oncology.

Prognostic Signifi cance of the Extent of Lymph Node Involvement in Stage IIN 1 Non-small Cell Lung Cancer

M. Liao, Q. Luo, Shun Lu, 2013 .

D-1553 (garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.

Yanqiu Zhao, N. Yang, Yiping Zhang, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Danyi Wen, Shun Lu, Zhiwei Chen, 2021, Cell biology international.

LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Ying Cheng, D. Carbone, L. Paz-Ares, 2020 .

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

E. Felip, A. Ardizzoni, Y. Min, 2021, EClinicalMedicine.

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Yunpeng Liu, Dong Wang, Juxian Wang, 2020 .

Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.

Xiangyun Ye, Yunhua Xu, Shun Lu, 2016, Medicinal chemistry (Shariqah (United Arab Emirates)).

SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4

Jia Huang, Q. Luo, Shun Lu, 2018, Journal of Experimental & Clinical Cancer Research.